SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-020833
Filing Date
2023-05-11
Accepted
2023-05-11 07:16:04
Documents
13
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pyxs-20230511.htm   iXBRL 8-K 54892
2 EX-99.1 pyxs-ex99_1.htm EX-99.1 210900
  Complete submission text file 0000950170-23-020833.txt   397337

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pyxs-20230511_pre.xml EX-101.PRE 10289
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pyxs-20230511.xsd EX-101.SCH 2472
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pyxs-20230511_lab.xml EX-101.LAB 14018
7 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20230511_htm.xml XML 4911
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

IRS No.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 23908799
SIC: 2834 Pharmaceutical Preparations